These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1622175)

  • 41. Penetration of fleroxacin and ciprofloxacin into skin blister fluid: a comparative study.
    Lubowski TJ; Nightingale C; Sweeney K; Quintiliani R; Zhi J
    Antimicrob Agents Chemother; 1992 Mar; 36(3):651-5. PubMed ID: 1622179
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of flecainide in patients with cirrhosis of the liver.
    McQuinn RL; Pentikäinen PJ; Chang SF; Conard GJ
    Clin Pharmacol Ther; 1988 Nov; 44(5):566-72. PubMed ID: 3141098
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Penetration of fleroxacin into human and animal tissues.
    Portmann R; Weidekamm E
    Chemotherapy; 1992; 38(3):145-9. PubMed ID: 1511632
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies.
    Reigner BG; Welker HA
    Antimicrob Agents Chemother; 1996 Mar; 40(3):575-80. PubMed ID: 8851573
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics after a single oral dose of bopindolol in patients with cirrhosis.
    Wensing G; Branch RA; Humbert H; Ohnhaus EE; Kirch W
    Eur J Clin Pharmacol; 1990; 39(6):569-72. PubMed ID: 1982762
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ascites dynamics in cirrhosis. Proposal and validation of a methylene blue dilution test.
    Milani A; Ciammella AM; Degen C; Siciliano M; Rossi L
    J Hepatol; 1992 Nov; 16(3):369-75. PubMed ID: 1336786
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis.
    Teunissen MW; Spoelstra P; Koch CW; Weeda B; van Duyn W; Janssens AR; Breimer DD
    Br J Clin Pharmacol; 1984 Nov; 18(5):707-15. PubMed ID: 6508980
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cirrhosis of the liver markedly impairs the elimination of mexiletine.
    Pentikäinen PJ; Hietakorpi S; Halinen MO; Lampinen LM
    Eur J Clin Pharmacol; 1986; 30(1):83-8. PubMed ID: 3709636
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comparison between antipyrine and aminopyrine blood clearances.
    Kawasaki S; Imamura H; Kokudo N; Bandai Y; Sanjo K; Idezuki Y
    Hepatogastroenterology; 1992 Aug; 39(4):344-6. PubMed ID: 1427580
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers.
    Nakashima M; Kanamaru M; Uematsu T; Takiguchi A; Mizuno A; Itaya T; Kawahara F; Ooie T; Saito S; Uchida H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():133-44. PubMed ID: 3144532
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid.
    Ferrara SD; Tedeschi L; Frison G; Orlando R; Mazzo M; Zordan R; Padrini R; Palatini P
    Eur J Clin Pharmacol; 1996; 50(4):305-10. PubMed ID: 8803524
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Altered kinetics of etozolin and its active metabolite ozolinone in hepatitis and hepatic cirrhosis with ascites.
    Knauf H; Missmahl M; Schölmerich J; Gerok W; Mutschler E
    Arzneimittelforschung; 1987 Dec; 37(12):1385-8. PubMed ID: 3449068
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tubular sodium handling in cirrhotic patients with ascites as analysed by the renal lithium clearance method.
    Diez J; Simon MA; Anton F; Indart FJ; Prieto J
    Eur J Clin Invest; 1990 Jun; 20(3):266-71. PubMed ID: 2114987
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics of oral fleroxacin in male and premenopausal female volunteers.
    Bertino JS; Nafziger AN
    Antimicrob Agents Chemother; 1996 Mar; 40(3):789-91. PubMed ID: 8851614
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.
    Baririan N; Van Obbergh L; Desager JP; Verbeeck RK; Wallemacq P; Starkel P; Horsmans Y
    Clin Pharmacokinet; 2007; 46(3):261-70. PubMed ID: 17328584
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of a fat- and calcium-rich breakfast on pharmacokinetics of fleroxacin administered in single and multiple doses.
    Bertino JS; Nafziger AN; Wong M; Stragand L; Puleo C
    Antimicrob Agents Chemother; 1994 Mar; 38(3):499-503. PubMed ID: 8203844
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quinolone pharmacokinetics and metabolism.
    Lode H; Höffken G; Boeckk M; Deppermann N; Borner K; Koeppe P
    J Antimicrob Chemother; 1990 Oct; 26 Suppl B():41-9. PubMed ID: 2124212
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Muscle sympathetic nerve activity and renal responsiveness to atrial natriuretic factor during the development of hepatic ascites.
    Morali GA; Floras JS; Legault L; Tobe S; Skorecki KL; Blendis LM
    Am J Med; 1991 Oct; 91(4):383-92. PubMed ID: 1835288
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics of aztreonam in patients with liver cirrhosis and ascites.
    el Touny M; el Guinaidy M; Abdel Barry M; Osman L; Sabbour MS
    J Antimicrob Chemother; 1992 Sep; 30(3):387-95. PubMed ID: 1452504
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics of dirithromycin in patients with mild or moderate cirrhosis.
    Mazzei T; Surrenti C; Novelli A; Biagini MR; Fallani S; Cassetta MI; Conti S; Surrenti E
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1556-9. PubMed ID: 10390202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.